2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 1436

Therapeutic Drug Monitoring on Rheumatoid Arthritis Patients with Reduced Doses of Intravenous Tocilizumab

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

9:00AM-11:00AM: Abstract Number: 1763

Time to Diagnosis of ANCA-Associated Vasculitides : Data from French Vasculitis Study Group Registry

Vasculitis Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1294

Time to Pregnancy in Women with Systemic Lupus Erythematosus

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1322

Tissue Folate Dysregulation Is Associated with Disease Activity and Methotrexate Response in Collagen-Induced Arthritis

Rheumatoid Arthritis – Animal Models Poster II

9:00AM-11:00AM: Abstract Number: 1399

Tissues Are Differently Modulated By Tocilizumab and Methotrexate; Assessment of Connective Tissue Metabolites in the Ambition Study

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1415

TNF-Induced IRF1 Is Critical for the Inflammatory Gene Expression in Fibroblast-like Synoviocytes

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1693

To What Extend Do Auto-Antibodies Help to Identify High-Risk Patients in Systemic Sclerosis?

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1645

Tobacco Exposure and Relationship with Severe Damage in Systemic Lupus Erythematosus Patients

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

9:00AM-11:00AM: Abstract Number: 1421

Tofacitinib Monotherapy Improves Arterial Stiffness in Conventional Dmards Active Rheumatoid Arthritis Patients. a Cohort Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

9:00AM-11:00AM: Abstract Number: 1741

Tolerance and Efficiency of Anti-Programmed Death 1 Antibodies in Patients with Cancer and Preexisting Autoimmune or Inflammatory Diseases

T Cell Biology and Targets in Autoimmune Disease Poster I

9:00AM-11:00AM: Abstract Number: 1686

Topical Nitroglycerine (NTG) Vs Matching Vehicle in Secondary Raynaud Phenomenon (RP) – a Double-Blind Crossover Study of Subjective and Physiologic Responses to Controlled Cold Challenge

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1492

Total Body Water Correlates with Ocular Sicca Symptoms in Primary SjöGren’s Syndrome

Sjögren's Syndrome Poster II: Clinical Research

9:00AM-11:00AM: Abstract Number: 1298

Tough Choices: Understanding the Medication Decision-Making Process for Women with Inflammatory Arthritis during Pregnancy and Lactation

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1103

Towards Recommendations on Functional Assessment Status Measures for Rheumatoid Arthritis: Preliminary Results from a Systematic Review

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1652

Trajectories of Quality of Life in an Iception Cohort of Lupus Patients and Their Determinants

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].